88 related articles for article (PubMed ID: 34726773)
1. Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma.
Leupin N; Zinzani PL; Morschhauser F; Dalle S; Maerevoet M; Michot JM; Ribrag V; Offner F; Beylot-Barry M; Moins-Teisserenc H; Zwaenepoel K; de Winne K; Battistella M; Hultberg A; Gandini D; Moshir M; Jacobs J; Delahaye T; Khan A; Zabrocki P; Silence K; van Rompaey L; Borg C; Motta G; Melle F; Calleri A; Pauwels P; de Haard H; Pileri S; Bagot M
Cancer; 2022 Mar; 128(5):1004-1014. PubMed ID: 34726773
[TBL] [Abstract][Full Text] [Related]
2. The novel high-affinity humanized antibody IMM40H targets CD70, eliminates tumors via Fc-mediated effector functions, and interrupts CD70/CD27 signaling.
Li S; Chen D; Guo H; Liu D; Yang C; Zhang R; Wang T; Zhang F; Bai X; Yang Y; Sun N; Zhang W; Zhang L; Zhao G; Peng L; Tu X; Tian W
Front Oncol; 2023; 13():1240061. PubMed ID: 37849799
[TBL] [Abstract][Full Text] [Related]
3. Phase II evaluation of VDC-1101 in canine cutaneous T-cell lymphoma.
Morges MA; Burton JH; Saba CF; Vail DM; Burgess KE; Thamm DH
J Vet Intern Med; 2014; 28(5):1569-74. PubMed ID: 25274443
[TBL] [Abstract][Full Text] [Related]
4. Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC.
Olsen EA; Whittaker S; Willemze R; Pinter-Brown L; Foss F; Geskin L; Schwartz L; Horwitz S; Guitart J; Zic J; Kim YH; Wood GS; Duvic M; Ai W; Girardi M; Gru A; Guenova E; Hodak E; Hoppe R; Kempf W; Kim E; Lechowicz MJ; Ortiz-Romero P; Papadavid E; Quaglino P; Pittelkow M; Prince HM; Sanches JA; Sugaya M; Vermeer M; Zain J; Knobler R; Stadler R; Bagot M; Scarisbrick J
Blood; 2022 Aug; 140(5):419-437. PubMed ID: 34758074
[TBL] [Abstract][Full Text] [Related]
5. Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma.
Phillips D; Matusiak M; Gutierrez BR; Bhate SS; Barlow GL; Jiang S; Demeter J; Smythe KS; Pierce RH; Fling SP; Ramchurren N; Cheever MA; Goltsev Y; West RB; Khodadoust MS; Kim YH; Schürch CM; Nolan GP
Nat Commun; 2021 Nov; 12(1):6726. PubMed ID: 34795254
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA Regulation of T-Cell Exhaustion in Cutaneous T Cell Lymphoma.
Han Z; Estephan RJ; Wu X; Su C; Yuan YC; Qin H; Kil SH; Morales C; Schmolze D; Sanchez JF; Tian L; Yu J; Kortylewski M; Rosen ST; Querfeld C
J Invest Dermatol; 2022 Mar; 142(3 Pt A):603-612.e7. PubMed ID: 34774537
[TBL] [Abstract][Full Text] [Related]
7. Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL.
Wilson WH; Wright GW; Huang DW; Hodkinson B; Balasubramanian S; Fan Y; Vermeulen J; Shreeve M; Staudt LM
Cancer Cell; 2021 Dec; 39(12):1643-1653.e3. PubMed ID: 34739844
[TBL] [Abstract][Full Text] [Related]
8. Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management.
Musiek ACM; Rieger KE; Bagot M; Choi JN; Fisher DC; Guitart J; Haun PL; Horwitz SM; Huen AO; Kwong BY; Lacouture ME; Noor SJ; Rook AH; Seminario-Vidal L; Vermeer MH; Kim YH
Dermatol Ther (Heidelb); 2022 Jan; 12(1):29-40. PubMed ID: 34816383
[TBL] [Abstract][Full Text] [Related]
9. Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma.
Jain P; Zhao S; Lee HJ; Hill HA; Ok CY; Kanagal-Shamanna R; Hagemeister FB; Fowler N; Fayad L; Yao Y; Liu Y; Moghrabi OB; Navsaria L; Feng L; Nogueras Gonzalez GM; Xu G; Thirumurthi S; Santos D; Iliescu C; Tang G; Medeiros LJ; Vega F; Avellaneda M; Badillo M; Flowers CR; Wang L; Wang ML
J Clin Oncol; 2022 Jan; 40(2):202-212. PubMed ID: 34797699
[TBL] [Abstract][Full Text] [Related]
10. Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial.
Forde PM; Anagnostou V; Sun Z; Dahlberg SE; Kindler HL; Niknafs N; Purcell T; Santana-Davila R; Dudek AZ; Borghaei H; Lanis M; Belcaid Z; Smith KN; Balan A; White JR; Cherry C; Ashok Sivakumar IK; Shao XM; Chan HY; Singh D; Thapa S; Illei PB; Pardoll DM; Karchin R; Velculescu VE; Brahmer JR; Ramalingam SS
Nat Med; 2021 Nov; 27(11):1910-1920. PubMed ID: 34750557
[TBL] [Abstract][Full Text] [Related]
11. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data.
Sehn LH; Hertzberg M; Opat S; Herrera AF; Assouline S; Flowers CR; Kim TM; McMillan A; Ozcan M; Safar V; Salles G; Ku G; Hirata J; Chang YM; Musick L; Matasar MJ
Blood Adv; 2022 Jan; 6(2):533-543. PubMed ID: 34749395
[TBL] [Abstract][Full Text] [Related]
12. PHOENIX rises: Genomic-based therapies for diffuse large B cell lymphoma.
Mondello P; Ansell SM
Cancer Cell; 2021 Dec; 39(12):1570-1572. PubMed ID: 34739842
[TBL] [Abstract][Full Text] [Related]
13. Risk of thyroid disorders in adult and childhood Hodgkin lymphoma survivors 40 years after treatment.
Macklin-Doherty A; Jones M; Coulson P; Bruce C; Chau I; Alexander E; Iyengar S; Taj M; Cunningham D; Swerdlow A
Leuk Lymphoma; 2022 Mar; 63(3):562-572. PubMed ID: 34738860
[TBL] [Abstract][Full Text] [Related]
14. Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 study.
Eyre TA; Schuh A; Wierda WG; Brown JR; Ghia P; Pagel JM; Furman RR; Cheung J; Hamdy A; Izumi R; Patel P; Wang MH; Xu Y; Byrd JC; Hillmen P
Lancet Haematol; 2021 Dec; 8(12):e912-e921. PubMed ID: 34735860
[TBL] [Abstract][Full Text] [Related]
15. Role of lenalidomide in the treatment of peripheral T-cell non-Hodgkin lymphomas.
Cencini E; Fabbri A; Mecacci B; Bocchia M
World J Clin Oncol; 2021 Oct; 12(10):882-896. PubMed ID: 34733611
[TBL] [Abstract][Full Text] [Related]
16. Venetoclax in Previously Treated Waldenström Macroglobulinemia.
Castillo JJ; Allan JN; Siddiqi T; Advani RH; Meid K; Leventoff C; White TP; Flynn CA; Sarosiek S; Branagan AR; Demos MG; Guerrera ML; Kofides A; Liu X; Munshi M; Tsakmaklis N; Xu L; Yang G; Patterson CJ; Hunter ZR; Davids MS; Furman RR; Treon SP
J Clin Oncol; 2022 Jan; 40(1):63-71. PubMed ID: 34793256
[TBL] [Abstract][Full Text] [Related]
17. Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trial.
Klein O; Kee D; Gao B; Markman B; da Gama Duarte J; Quigley L; Jackett L; Linklater R; Strickland A; Scott C; Mileshkin L; Palmer J; Carlino M; Behren A; Cebon J
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34782426
[TBL] [Abstract][Full Text] [Related]
18. Targeting Epigenetic Modifiers Can Reduce the Clonogenic Capacities of Sézary Cells.
Chebly A; Prochazkova-Carlotti M; Idrissi Y; Bresson-Bepoldin L; Poglio S; Farra C; Beylot-Barry M; Merlio JP; Tomb R; Chevret E
Front Oncol; 2021; 11():775253. PubMed ID: 34765562
[TBL] [Abstract][Full Text] [Related]
19. The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia.
Langerbeins P; Zhang C; Robrecht S; Cramer P; Fürstenau M; Al-Sawaf O; von Tresckow J; Fink AM; Kreuzer KA; Vehling-Kaiser U; Tausch E; Müller L; Eckart MJ; Schlag R; Freier W; Gaska T; Balser C; Reiser M; Stauch M; Wendtner CM; Fischer K; Stilgenbauer S; Eichhorst B; Hallek M
Blood; 2022 Jan; 139(2):177-187. PubMed ID: 34758069
[TBL] [Abstract][Full Text] [Related]
20. Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors.
Hong DS; Rixe O; Chiu VK; Forde PM; Dragovich T; Lou Y; Nayak-Kapoor A; Leidner R; Atkins JN; Collaku A; Fox FE; Marshall MA; Olszanski AJ
Clin Cancer Res; 2022 Feb; 28(3):479-488. PubMed ID: 34753777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
